Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 71, Issue 12, 2010, Pages 1680-1688

  Winhusen, Theresa M ^a   Somoza, Eugene C ^a,b   Brigham, Gregory S ^a,c   Liu, David S ^d   Green, Carla A ^e   Covey, Lirio S ^f   Croghan, Ivana T ^g   Adler, Lenard A ^b   Weiss, Roger D ^h,i   Leimberger, Jeffrey D ^j   Lewis, Daniel F ^a   Dorer, Emily M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Maryhaven   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^g MAYO CLINIC   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ MCLEAN HOSPITAL   (United States)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; NICOTINE PATCH; PLACEBO;

ADULT; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BACKACHE; BLOOD PRESSURE; CIGARETTE SMOKING; CONNECTIVE TISSUE DISEASE; COUGHING; DECREASED APPETITE; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HEART RATE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SIDE EFFECT; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; UNPLEASANT DREAM; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COMBINED MODALITY THERAPY; COUNSELING; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; NICOTINE; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 78650464201     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05089gry     Document Type: Article

References (44)

1. Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 1997-2001. MMWR Morb Mortal Wkly Rep. 2005;54(25):625-628.
2. Hall SM. Nicotine interventions with comorbid populations. Am J Prev Med. 2007;33(suppl):S406-S413.
3. Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997;36(1):37-44.
4. Pomerleau OF, Downey KK, Stelson FW, et al. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse. 1995;7(3):373-378.
5. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil. 1998;31(6):533-544.
6. Wilens TE, Vitulano M, Upadhyaya H, et al. Cigarette smoking associated with attention deficit hyperactivity disorder. J Pediatr. 2008;153(3):414-419.
7. Levin ED, Conners CK, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 1996;123(1):55-63.
8. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
9. Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol. 2007;32(6):631-642.
10. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005;47(6):565-572.
11. Castle L, Aubert RE, Verbrugge RR, et al. Trends in medication treatment for ADHD. J Atten Disord. 2007;10(4):335-342.
12. Conners CK, Levin ED, Sparrow E, et al. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull. 1996;32(1):67-73.
13. Levin ED, Conners CK, Silva D, et al. Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol. 2001;9(1):83-90.
14. Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol. 2007;74(8):1212-1223.
15. Monuteaux MC, Spencer TJ, Faraone SV, et al. A randomized, placebocontrolled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2007;68(7):1094-1101. (Pubitemid 47340332)
16. Wilens TE, Spencer T. The stimulants revisited. In: Stubbe C, ed. Child and Adolescent Psychiatric Clinics of North America. 3rd ed. Philadelphia, PA: Saunders; 2000:573-603.
17. Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? a meta-analysis. CMAJ. 2001;165(11): 1475-1488. (Pubitemid 34060190)
18. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry. 1999;38(5):503-512.
19. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108(4):883-892.
20. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry. 2006;163(3):387-395.
21. Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med. 2006;160(1):82-90.
22. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-835.
23. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981-989.
24. Bekker EM, Böcker KBE, Van Hunsel F, et al. Acute effects of nicotine on attention and response inhibition. Pharmacol Biochem Behav. 2005;82(3):539-548.
25. McClernon FJ, Kollins SH, Lutz AM, et al. Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study. Psychopharmacology (Berl). 2008;197(1): 95-105.
26. Wilens TE, Prince JB, Spencer TJ, et al. Stimulants and sudden death: what is a physician to do? Pediatrics. 2006;118(3):1215-1219. (Pubitemid 46090066)
27. Rush CR, Higgins ST, Vansickel AR, et al. Methylphenidate increases cigarette smoking. Psychopharmacology (Berl). 2005;181(4):781-789.
28. Vansickel AR, Stoops WW, Glaser PEA, et al. A pharmacological analysis of stimulant-induced increases in smoking. Psychopharmacology (Berl). 2007;193(3):305-313.
29. Medscape Today. FDA Safety Changes: Allegra, Cymbalta, Concerta. (http://www.medscape.com/viewarticle/550192). Accessed September 26, 2008.
30. Adler L, Spencer T. The Adult ADHD Clinical Diagnostic Scale (ACDS) Version 1.2. New York, NY: New York University School of Medicine; 2004.
31. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, NY: The Guilford Press; 1998.
32. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Allen J, Litten R, eds. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Totowa, NJ: Humana Press, Inc; 1992:41-72.
33. Fals-Stewart W, O'Farrell TJ, Freitas TT, et al. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol. 2000;68(1):134-144. (Pubitemid 30120958)
34. Hughes JR, Keely JP, Niaura RS, et al. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5(1):13-25. (Pubitemid 36285465)
35. Hurt RD, Krook JE, Croghan IT, et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncol. 2003;21(5):914-920.
36. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/ hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2): 187-201. (Pubitemid 38452762)
37. National Institute of Mental Health. CGI (Clinical Global Impressions) Scale - NIMH. Psychopharmacol Bull. 1985;21:839-844.
38. Adler LA, Spencer T, Faraone SV, et al. Training raters to assess adult ADHD: reliability of ratings. J Atten Disord. 2005;8(3):121-126. (Pubitemid 40805795)
39. SAS [computer program]. Version 9.1.3. Cary, NC: SAS Institute; 2007
40. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008; (1, issue 1)CD000146. 10.1002/14651858.CD000146.pub3. (Pubitemid 351807619)
41. Covey LS, Manubay J, Jiang H, et al. Smoking cessation and inattention or hyperactivity/impulsivity: a post hoc analysis. Nicotine Tob Res. 2008;10(12):1717-1725.
42. Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA. 1994;271(24): 1940-1947. (Pubitemid 24177103)
43. Cousins MS, Stamat HM, de Wit H. Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl). 2001;157(3):243-253.
44. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services; 2008.